Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281937 · ClinicalTrials.gov registry record · Phase 2
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A Phase 2 study of Obesity and Overweight, sponsored by Verdiva Bio Dev Limited.
- Active
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT07281937: Active Phase 2 study of Obesity and Overweight, sponsored by Verdiva Bio Dev Limited.
NCT07281937 is a Phase 2 study of Obesity and Overweight that is active but no longer recruiting, run by Verdiva Bio Dev Limited. The registered enrollment target is 206 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07281937, a Phase 2 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Verdiva Bio Dev Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VRB-101
Study Locations (20)
California
- Clinical Study Site 111 - Anaheim
- Clinical Study Site 107 - Montclair
- Clinical Study Site 118 - Tarzana
Alabama
- Clinical Study Site 103 - Anniston
- Clinical Study Site 109 - Cullman
New York
- Clinical Study Site 117 - Binghamton
- Clinical Study Site 101 - Rochester
North Carolina
- Clinical Study Site 120 - Charlotte
- Clinical Study Site 108 - Monroe
Arizona
- Clinical Study Site 110 - Phoenix
Arkansas
- Clinical Study Site 113 - Little Rock
Georgia
- Clinical Study Site 119 - Decatur
Iowa
- Clinical Study Site 116 - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2025-11-25 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07281937
The ClinicalTrials.gov registry entry for NCT07281937 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (75% lower). The listed sponsor is Verdiva Bio Dev Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07281937 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Alabama, New York.
Frequently Asked Questions
What is clinical trial NCT07281937 about?
NCT07281937 is a clinical study titled "A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities". The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
What is the current status of trial NCT07281937?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2025-11-25. Estimated completion is 2026-08.
What conditions does trial NCT07281937 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07281937?
The interventions under investigation include: Placebo (DRUG), VRB-101 (DRUG).
Who is sponsoring clinical trial NCT07281937?
This trial is sponsored by Verdiva Bio Dev Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07281937 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.